| Issue |
Parasite
Volume 1, Number 1S, March 1994
3rd CEC Filariasis Network Meeting (Lisbon -IHMT, 4-7 September 1993)
|
|
|---|---|---|
| Page(s) | S25 - S27 | |
| DOI | https://doi.org/10.1051/parasite/199401s1025 | |
| Published online | 01 October 2014 | |
From the laboratory to the home of the patient infected with Onchocerca volvulus (O. v): clinical experience with amocarzine (preliminary results)
PD Dr., med. A.A. Poltera, Ciba-Geigy, Ltd, Pharma Division, Dept. of Medicine, K-24-4-09, CH-4002 Basle / Switzerland.
If dosed correctly, amocarzine has onchocercacidal effects with acceptable clinical tolerability. Up to now over 1 900 patients were exposed to an initial amocarzine regimen and over 500 have been re-exposed to amocarzine 2 years after initial therapy. Amocarzine is a promising onchocercacidal drug and a potential candidate for onchocerciasis control programmes.
Key words: onchocerciasis / chemotherapy / amocarzine
© PRINCEPS Editions, Paris, 1994, transferred to Société Française de Parasitologie
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.